Surgical Antibiotic Prophylaxis in an Era of Antibiotic Resistance: Common Resistant Bacteria and Wider Considerations for Practice

Abstract: The increasing incidence of antimicrobial resistance (AMR) presents a global crisis to healthcare, with longstanding antimicrobial agents becoming less effective at treating and preventing infection. In the surgical setting, antibiotic prophylaxis has long been established as routine standard of care to prevent surgical site infection (SSI), which remains one of the most common hospital-acquired infections. The growing incidence of AMR increases the risk of SSI complicated with resistant bacteria, resulting in poorer surgical outcomes (prolonged hospitalisation, extended durations of antibiotic therapy, higher rates of surgical revision and mortality). Despite these increasing challenges, more data are required on approaches at the institutional and patient level to optimise surgical antibiotic prophylaxis in the era of antibiotic resistance (AR). This review provides an overview of the common resistant bacteria encountered in the surgical setting and covers wider considerations for practice to optimise surgical antibiotic prophylaxis in the perioperative setting.

Keywords: antibiotic resistance, perioperative care, surgical antibiotic prophylaxis, surgical site infection, antimicrobial stewardship

Introduction

Antimicrobial resistance (AMR) presents a modern global crisis. The incidence of AMR is rapidly increasing and infection-related mortality is expected to exceed 10 million cases per year by 2050.1 Over the past decade, the emergence of AMR across fungal, viral, bacterial, and protozoal infections is increasingly reported.2 Resistance has been highlighted in recent times to various microbes, including fungal infection with Candida auris, which is showing growing resistance to many first-line anti-fungal treatments.3 AMR is set to exceed current annual cancer-related deaths world-wide by 2050.1 While the emergence of AMR occurs across the microbiome, bacterial resistance poses the greatest threat with longstanding antibiotics becoming less effective at treating and preventing bacterial infection, resulting in poorer patient and surgical outcomes.4,5

Globally, multiple factors contribute to increasing prevalence of antibiotic-resistant organisms, including social determinants, economic factors, provision and governance of healthcare, and environmental factors, all of which impact on both humans and animals.6,7 Additionally, inappropriate antibiotic use is becoming an increasing concern as a major contributor to the emergence of AMR.8,9 The US Centers for Disease Control and Prevention (CDC-US) reports a concerning increase in the prevalence of AMR, with at least 2.8 million people suffering
from a drug-resistant infection each year in the US alone, and 35,000 of these subsequently dying.10 Similarly, throughout Europe, it is estimated that approximately 33,000 patients die each year due to drug-resistant infections, of which more than half are healthcare-acquired.11 The actual world-wide prevalence of people affected with drug-resistant bacteria is likely to be much larger, as data drawn from many low- and middle-income countries are scarce.12

In the surgical setting, antibiotic resistance (AR) leads to prolonged hospitalisation, extended durations of antibiotic therapy, higher rates of mortality, increased need for surgical revision, and requirement for novel antibiotics which may have increased toxicity.13 Across the United States, Europe and Australia, expenditure on AMR and its sequelae is expected to cost approximately USD 3.5 billion annually.14 Longer term, the cumulative global expenditure between now and 2050 on AMR and its sequelae is expected to exceed USD $100 trillion.1 Despite our advances and increasing knowledge on this topic, AR remains a critical consideration for the clinician and an important barrier for successfully preventing surgical site infection (SSI).9 SSIs are one of the most prevalent hospital-acquired infections, and AR poses significant risks in surgery due to commonplace antibiotics having limited or no effect against some resistant organisms.15

This review aims to provide insight on common resistant bacteria, which pose a threat in surgery and any ensuring SSI that may develop. We discuss common methods to optimise current surgical antibiotic prophylaxis (SAP) and highlight broader considerations for mitigating the risk of SSI in the setting of AR.

The Role of Surgical Antibiotic Prophylaxis

SSI is defined as occurring in the superficial, deep or organ space around the surgical site within 30 days of the surgical procedure, or within 1 year of implants in-situ.16 In attempts to classify risks of developing SSI, factors including patient age, sex, surgery type and duration, American Society of Anesthesiologists (ASA) grade, and assessment of wound contamination score are routinely assessed.17 Wound contamination assessment is undertaken prior to and during surgery. Wounds are classified by the CDC-US as clean, clean-contaminated, contaminated and dirty/infected.18 The inclusion of the ASA grade acknowledges the potential impact of patient functional capacity (fitness) and long-term conditions as contributing factors to infection risk.17 While providing insight to infection risk, guidance is lacking on these classifications regarding how to assess, prevent and manage patients with an increased risk of carrying or acquiring antibiotic-resistant organisms and ultimately SSI.

The rationale of SAP is to deliver adequate antibiotic exposure throughout the surgical site to cover the organisms commonly associated with SSI for a procedure (Table 1).19 The pooled rate of SSI across all surgeries when stratified by wound class is approximately 1.3–2.9% for clean, 2.4–7.7% for clean-contaminated, 6.4–15.2% for contaminated and 7.1–40% for dirty.20 In many clean, clean-contaminated, and contaminated procedures, SAP is employed as a routine standard of care demonstrating good safety and efficacy. Dirty procedures are considered as established infections and thus, a targeted treatment approach is generally indicated. An international multicentre study of SSIs post gastrointestinal surgery provides some confronting results when stratified by country income status using the United Nations Human Development Index (HDI). In this prospective study, cohort analysis of 610 patients that had both an SSI and microbiology culture result, 132 (21.6%) acquired an infection with an organism resistant to the SAP administered. Low-HDI countries reported resistant infections in 46/128 (36%) of patients compared to 37/187 (20%) in middle-HDI countries and 49/295 (16.6%) in high-HDI countries.21

AR is a threat across both primary healthcare (general/family practice, residential aged care facilities), secondary and tertiary care (hospitalisations). However, AR remains especially problematic in areas with high usage of antibiotics (intensive and critical care, and perioperative care),22–24 and in lower HDI country contexts.21 Three common organisms associated with resistance include Staphylococcus aureus in approximately 50% of the cases, followed by Escherichia coli (17%), and Pseudomonas aeruginosa (10%). Infection with resistant Klebsiella pneumoniae, Proteus mirabilis, Enterobacter aerogenes, and non-fermenting Gram-negative bacterial infections also regularly occur.23

Antibiotic selection for SAP is dependent on local resistance patterns and institutional protocols, though most SAP regimens are selected by their spectrum of antibiotic activity in relation to the procedure performed. This assumes that local resistance patterns are known, and institutional protocols are in place and adhered to.

Narrower spectrum first-generation cephalosporins (ie, cefazolin) are common antibiotics utilised for SAP. Cephalosporins are widely used due to their spectrum of
Examples of Bacteria Associated with Surgical Site Infection*  
VRE, ESBL producers, FR-GNB, CRE  
Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus  
MRSA, VRE, ESBL producers  
Examples of Possible Antibiotic  
Resistance Encountered  
MRSA, ESBL producers  
VRE, ESBL producers, CRE  
MRSA, VRE, ESBL producers  
MRSA, ESBL producers  
MRSA, ESBL producers  
MRSA, ESBL producers  
VRE, ESBL producers, FR-GNB, CRE  
MRSA, VRE, ESBL producers

Table 1: Examples of Bacteria Implicated in Surgical Site Infection Categorised by Surgical Procedure

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Example of Bacteria Associated with Surgical Site Infection*</th>
<th>Examples of Possible Antibiotic Resistance Encountered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiothoracic surgery</td>
<td>Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus spp., Corynebacterium spp., Enterobacterales*</td>
<td>MRSA, ESBL producers</td>
</tr>
<tr>
<td>Gastrointestinal surgery</td>
<td>Enterococcus spp., Gram-positive cocci (Streptococcus spp.), Enterobacterales**, anaerobes</td>
<td>VRE, ESBL producers, CRE</td>
</tr>
<tr>
<td>Gynaecological surgery</td>
<td>Staphylococcus aureus, Group B Streptococcus, Enterococcus spp., Enterobacterales**</td>
<td>MRSA, VRE, ESBL producers</td>
</tr>
<tr>
<td>Head, oral and neck surgery</td>
<td>Staphylococcus aureus, Enterobacterales**, Pseudomonas aeruginosa, anaerobes</td>
<td>MRSA, ESBL producers</td>
</tr>
<tr>
<td>Neurosurgical surgery</td>
<td>Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus spp., Corynebacterium spp., Enterobacterales**, Pseudomonas aeruginosa, anaerobes</td>
<td>MRSA, ESBL producers</td>
</tr>
<tr>
<td>Orthopaedic surgery</td>
<td>Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus spp., Enterobacterales**, Pseudomonas aeruginosa, anaerobes</td>
<td>MRSA, ESBL producers</td>
</tr>
<tr>
<td>Urological surgery</td>
<td>Gram-negative bacilli, Enterococcus spp., Enterobacterales**</td>
<td>VRE, ESBL producers, FR-GNB, CRE</td>
</tr>
<tr>
<td>Vascular surgery</td>
<td>Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus spp., Enterobacterales**, Pseudomonas aeruginosa</td>
<td>MRSA, VRE, ESBL producers</td>
</tr>
</tbody>
</table>

Notes: Table 1 shows examples of bacteria and antibiotic resistance encountered in surgical site infection by surgical procedure. *Table is not exhaustive of all possible organisms and bacterial resistance associated with surgical site infection, resistance may vary across different institutions, always follow site-specific resistance patterns and protocols where available. **Common examples of Enterobacterales in surgical site infections include: Escherichia coli, Klebsiella pneumoniae.  
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; ESBL, producers, extended-spectrum β-lactamase-producing bacteria; VRE, vancomycin-resistant Enterococcus; CRE, carbapenem-resistant Enterobacterales; FR-GNB, fluoroquinolone-resistant Gram-negative bacteria.

activity (on commensal skin flora, and some Gram-negative bacteria), favourable safety profile, and extensive experience in SAP. Additional coverage for Gram-negative bacteria and anaerobes is occasionally utilised, often with aminoglycosides (gentamicin) for Gram-negative bacteria and nitroimidazole agents (eg metronidazole or tinidazole) for anaerobes. Standard SAP is often hindered by the presence of β-lactam allergy, whereby immediate hypersensitivity to penicillins or cephalosporins necessitates use of alternate classes of antibiotics such as lincosamides (clindamycin, lincomycin) or glycopeptides (vancomycin, teicoplanin) for Gram-positive coverage. Moreover, the routine use of vancomycin in place of cefazolin is discouraged in the absence of methicillin-resistant S. aureus (MRSA) and/or cephalosporin allergy due to reduced efficacy and the potential to drive AR. Currently, there is limited guidance on selecting appropriate SAP in patients colonised with antibiotic-resistant bacteria, mostly due to an absence of established clinical trials and published data. A targeted approach using alternative antibiotics based on spectrum of activity in discussion with infectious diseases/medical microbiology may be considered if the resistant bacteria pose a significant risk of SSI (Table 2). Clinician discretion is imperative as unnecessary use of broader spectrum agents may exacerbate local resistance profiles.

Patient-Specific Risk Factors for SSI
Patient-specific risk factors such as older age, obesity, active smoking status, medical comorbidities, ASA-grade and use of immunosuppressive drugs can influence the risk of SSI and postoperative mortality. In low-income and middle-income countries, risk of SSI and postoperative mortality is greater than high-income countries. In the perioperative period, factors influencing SSI risk include availability, selection of antibiotic, timing and dose of antibiotic agent, and appropriate antiseptic preparation of the skin. During surgery, physiological factors affecting the risk of SSI include the presence of hyperglycaemia, trauma, shock, requirement for blood transfusion, hypoxia and hypothermia. In addition, some patients may be known or at risk of carriage of multidrug-resistant organisms (MROs), which preclude the use of first-line SAP agents. Risk factors to consider...
Table 2: Common Agents in Surgical Antibiotic Prophylaxis and Possible Alternatives for Consideration

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Antibiotic Class</th>
<th>Bacterial Coverage</th>
<th>Role in Surgical Antibiotic Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Common agents used in surgical antibiotic prophylaxis</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>β-lactam</td>
<td>Gram-positive ++</td>
<td>Gram-positive and limited Gram-negative cover. Common for many surgical procedures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative +</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes +</td>
<td></td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Lincosamide</td>
<td>Gram-positive ++</td>
<td>Gram-positive cover, typically reserved for patients with immediate hypersensitivity to β-lactam antibiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative -</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes ++</td>
<td></td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Aminoglycoside</td>
<td>Gram-positive -</td>
<td>Gram-negative cover, commonly used in urological and gastrointestinal surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative +++</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes -</td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Glycopeptide</td>
<td>Gram-positive +++</td>
<td>Gram-positive cover, typically reserved for patients with immediate hypersensitivity to β-lactam antibiotics or patients with MRSA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative -</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes ++</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alternative agents for consideration as surgical antibiotic prophylaxis in antibiotic resistance*</td>
</tr>
<tr>
<td>Meropenem/</td>
<td>Carbapenem</td>
<td>Gram-positive ++</td>
<td>Consider for ESBL producers and sensitivity to carbapenems. Avoid in suspected immediate hypersensitivity to β-lactams</td>
</tr>
<tr>
<td>Ertapenem</td>
<td></td>
<td>Gram-negative +++</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes ++</td>
<td></td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>Oxazolidinone</td>
<td>Gram-positive +</td>
<td>Consider for transrectal prostate biopsy in patients complicated with or suspected fluoroquinolone resistant bacteria (mostly E. coli)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative ++</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes -</td>
<td></td>
</tr>
<tr>
<td>Daptomycin</td>
<td>Cyclic lipopeptide</td>
<td>Gram-positive +++</td>
<td>Consider for VRE. Could also be considered for MRSA where vancomycin or teicoplanin contraindicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative -</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes +</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>Oxazolidinone</td>
<td>Gram-positive +++</td>
<td>Consider for VRE. Could also be considered for MRSA where vancomycin or teicoplanin contraindicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative -</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes +</td>
<td></td>
</tr>
<tr>
<td>Tigecycline</td>
<td>Glycylccline</td>
<td>Gram-positive ++</td>
<td>Consider for cover of VRE and MRSA where vancomycin, daptomycin and/or linezolid are contraindicated. Avoid in suspected hypersensitivity to tetracyclines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gram-negative ++</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaerobes ++</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Table 2 shows examples of common agents used in surgical antibiotic prophylaxis and examples of alternatives that could be considered in resistant bacteria based on their underlying spectrum of activity. Definitions. +++Indicates high degree of antibiotic activity, ++Indicates moderate degree of antibiotic activity, +Indicates low degree of antibiotic activity, -Indicates minimal to no antibiotic activity. *There is limited evidence comparing the efficacy of surgical antibiotic prophylaxis with alternative agents for resistant bacteria, unnecessary use may potentiate resistance and judicious selection is recommended in conjunction with infectious diseases/medical microbiology guidance. Abbreviations: MRSA, methicillin-resistant S. aureus; ESBL producers, extended-spectrum β-lactamase-producing bacteria; VRE, vancomycin-resistant Enterococcus.
include recent antibiotic usage, travel or residence in jurisdictions with high rates of AR, known or prior colonisation with MROs, or exposure to health facilities (intensive care units, hospitals/care facilities) with high rates of MROs. Collectively, there are many steps in the patient’s surgical journey that can influence SSI risk (Figure 1). Structural measures, for example, the use of laminar airflow in orthopaedic operating theatres have been implemented in some high-income settings to support reduction in SSI, although their effectiveness has been questioned.

**Gram-Positive Antibiotic Resistance of Concern in Surgical Antibiotic Prophylaxis**

**MRSA and Vancomycin-Resistant S. aureus (VRSA)**

*S. aureus* is an important organism in the human microbiome, remaining the most common organism associated with cutaneous infection. It has widespread presence as a commensal organism on the skin, skin-folds, and external nares of the nose. In the perioperative setting, *S. aureus* remains the most common organism associated with SSI, with a majority of *S. aureus* isolates sensitive to first-line narrow spectrum penicillins and cephalosporins (flucloxacillin, nafcillin, cefazolin). While the longstanding use of first-line penicillins and cephalosporins is routinely effective in preventing these infections, the emergence of resistance to β-lactams is challenging for SAP selection.

The emergence of MRSA dates back to the mid-20th century where isolates of *S. aureus* showed alterations to penicillin binding protein 2a (*PBP2a*). Vancomycin overcomes this resistance mechanism by targeting an alternate pathway via inhibition of *S. aureus* peptidoglycan synthesis. Nowadays, the use of vancomycin is integrated into SAP practice for patients previously colonised with MRSA, at high-risk of MRSA carriage or exposure to institutions with high prevalence of MRSA.

The incidence of *S. aureus* resistance is increasing throughout the world, with the World Health Organization (WHO) Global Report on AMR and Surveillance identifying 20% of *S. aureus* isolates worldwide as MRSA, with some regions reporting rates ≥80%. In the early 2000s, there was the emergence of vancomycin-resistant *S. aureus* (VRSA), which is recognised as a concern and high priority by the CDC-US and WHO. While VRSA has been documented across the globe, the absolute rates of infection remain low and there are minimal reports of transmissions across patients, particularly in the healthcare setting. Despite small incidences, reports of infection since 2010 have doubled, with the highest increases seen in the United States and throughout Asia. Surgical recommendations, management and data remain isolated to a series of case reports of VRSA.

![Image](https://example.com/image.png)

**Figure 1** Stages affecting risk of surgical site infection with antibiotic-resistant bacteria.

**Notes:** Obesity: body mass index ≥35kg/m², requiring fluid resuscitation: requirement of blood transfusion and/or intravenous fluids due to excessive blood loss (exceeding 1500mL).

**Abbreviation:** AR, antibiotic resistance.
Vancomycin-Resistant Enterococcus (VRE)

Many of the approximately 12 Enterococcus spp. can harbor vancomycin resistance. Patients can be colonised with one or multiple species, including E. faecalis, E. faecium, E. gallinarum, E. casseliflavus, E. avium, and E. mundtii. Clinically, vancomycin resistance is most important in E. faecium and E. faecalis. A prevalence study in the US consisting of over 24,179 patients with hospital-acquired bacteraemia, approximately 9% were Enterococcus spp. with two-thirds of E. faecium isolates displaying resistance to vancomycin. While there are many phenotypes of resistance within the Enterococcus spp., VRE often occurs in E. faecalis and E. faecium as phenotypes VanA or VanB, resulting in target binding-site alteration. Both are inducible on administration of glycopeptides, with VanA typically conferring resistance to vancomycin and teicoplanin, and VanB conferring resistance to vancomycin alone.

The CDC-US reported down-trending VRE infections in the US between 2012 and 2017 (84,000 down to 54,500 cases) as a testament to improved infection control practices and antibiotic stewardship. Alarming, in some other countries such as Germany, an increasing prevalence of SSI with VRE is observed with reports showing VRE infection increasing from 1% to 5% of all SSI between 2007 and 2016. Globally, it is estimated that carriage of VRE is increasing, though VRE colonisation does not always manifest to infection with VRE. Enterococcus spp. show intrinsic resistance to cephalosporins, clindamycin, penicillins and trimethoprim/sulfamethoxazole. Patients with VRE colonisation may require SAP with agents such as linezolid or daptomycin to reduce the risk of SSI, particularly in the context of abdominal surgery.

Gram-Negative Antibiotic Resistance of Concern in Surgical Antibiotic Prophylaxis

β-lactamase and Carbapenemase-Producing Gram-Negative Bacteria

β-lactamase production can render cephalosporin, penicillin and carbapenem type β-lactam antibiotics ineffective. Carriage with resistant Enterobacterales is increasing, with common examples of β-lactamase-producing organisms including E. coli, Klebsiella spp, and Enterobacter spp. In addition to Enterobacterales, P. aeruginosa is another common organism-producing β-lactamase and is considered to be an increasing concern among SSI. β-lactamases exist in molecular subclasses A, B, C and D, determined by amino acid sequence, of which each resistance profile can be grouped by phenotype and bacterial isolate. Three groups, defined by Bush et al, include the following: group 1 (cephalosporinases), group 2 (serine β-lactamases) and group 3 (metallo-β-lactamases). Group 1 and 2 β-lactamases hydrolyse the β-lactam antibiotic via serine mediated catabolism of the β-lactamase enzyme active site, whereas group 3 metallo-β-lactamases require catalysis by a cation – most commonly zinc 2+ at the active site. Two common terms used frequently throughout the literature to illustrate carbapenem resistance are carbapenem-resistant Enterobacterales (CRE) and a subset of this in which the mechanism of resistance is mediated by carbapenemase production (carbapenemase-producing Enterobacterales (CPE). CPE remains the most concerning mechanism driving carbapenem resistance.

Group 1 cephalosporinases comprise molecular subclass C and a common representative enzyme (AmpC). AmpC-mediated resistance occurs by hydrolysis of narrow spectrum cephalosporins (cefazolin, cefalexin), though increased and repeated exposure to cephalosporins can induce AmpC production – leading to resistance to broader-spectrum cephalosporins ceftriaxone, cefazidine and cefotaxime. This is concerning as common β-lactamase inhibitors such as clavulanic acid and tazobactam are generally ineffectual at overcoming such resistance mechanisms and the presence of other resistance mechanisms such as extended-spectrum β-lactamases (ESBL) can co-exist. Recent advances have seen the advent of the β-lactamase inhibitor avibactam, which is used in combination with broad spectrum cephalosporin agent ceftazidime in attempts to provide efficacy for AmpC-mediated resistance.

Group 2 serine β-lactamases consist of molecular subclasses A and D, with common representative enzymes and their many respective enzymes variants (Class A: PC, TEM, SHV, CepA, KPC; and, Class D: OXA). Following their characterisation was the development of β-lactamase inhibitors clavulanic acid and tazobactam, though resistance has also emerged to these agents. β-lactamases within subgroup 2be and group 2d are ESBL and are associated with the greatest emergence of resistance with an approximately 8-fold increase in identified variants over a 20-year period. In the surgical setting,
ESBL-producing Enterobacterales have shown a prevalence of approximately 15%, which is expected to grow sharply over the coming years. ESBLs show increased resistance to broader spectrum penicillins and cephalosporins. The reader is referred to Bush et al for a comprehensive overview on the many enzyme sub-classes and complexities of ESBL-producing bacteria.

Carbapenemase produced in K. pneumoniae (KPC) is an important class A enzyme, first identified in the US in 2001; shortly after multiple variants (KPC-2, to KPC-11) were discovered worldwide. KPC has emerged as one of the most common carbapenem resistance mechanisms across the US, China, South America and Greece. While KPC is most common in K. pneumoniae, other organisms harbouring KPC include both Enterobacterales and non-Enterobacterales (P. aeruginosa, Acinetobacter spp.). The presence of KPC-producing bacteria hinders the efficacy of antibiotics used for SAP, as routine cephalosporins are precluded by class-A β-lactamase hydrolysis. SAP in such instances may require sensitivity-guided/targeted prophylaxis or combinations of aminoglycosides, polymyxins, tigecycline, fosfomycin or ceftazidime/avibactam.

Group 3, Class B metallo-β-lactamases (MBL), differ functionally and structurally to their serine counterparts by the presence of zinc 2+ at the enzyme active site. Common representative enzymes and variants (IMP, VIM, NDM) confer resistance to carbapenems, oxyimino-β-lactams, β-lactamase inhibitors and monobactams. MBL-mediated carbapenem resistance is the commonest mechanism across Europe, Scandinavia and India.

Fluoroquinolone-Resistant Gram-Negative Bacteria (FR-GNB)

Fluoroquinolones (quinolones) are effective first-line SAP agents in urological procedures such as transrectal prostatic biopsy or for patients with confirmed β-lactam allergy (IgE mediated) to first-line agents. Quinolones (eg, oral ciprofloxacin) are also effective against P. aeruginosa.

Traditionally, quinolones are used predominantly for the prevention and treatment of Gram-negative organisms, via their effect on inhibition of DNA gyrase. Additionally, quinolones also target topoisomerase IV, inhibiting the relaxation of coiled DNA. Resistance occurs predominantly due to mutations of DNA gyrase subunits GyrA/GyrB and/or topoisomerase IV subunit ParC/ParE. Further, co-existence of resistance to quinolones can occur by reduced membrane permeability and/or overexpression of drug efflux pumps.

Recent exposure to quinolones (surgical prophylaxis or treatment) is a known risk factor for acquired quinolone resistance. A meta-analysis by Zhu et al highlights the significant increase of resistance of E. coli in those with recent fluoroquinolone use (OR 7.67; 95% CI 4.79–12.26). In addition to acquired quinolone resistance, transfer of plasmids containing resistance genes qnrA, qnrB, qnrS are of growing concern within the hospital environment. QnrA, qnrB and qnrS prevent quinolone effects at DNA gyrase/topoisomerase IV and are hypothesised to contribute and potentiate quinolone resistance, though their effect is not entirely understood. Resistance to quinolones is increasing globally, threatening many elements of modern medicine including SAP.

Optimising Current Practice Across the Patient Pathway

Revisiting Patient Allergy Status

Patient allergy status is an important consideration when it comes to selecting a suitable agent for SAP. Inappropriate or spurious patient labelling of antibiotic allergies is problematic. A recent multicentre UK study of hospitalised patients with common infections found that two-thirds of those patients with documented penicillin allergy had no details recorded on their purported allergy, yet those listed with penicillin allergy to have a 50% increased SSI risk which was largely due to patients receiving second-line agents for SAP. In addition, the labelling of penicillin allergy can lead to increased length of hospital stay, admission into intensive care units, increased hospital readmission rates and the promotion of antibiotic resistance.

A US study by Blumenthal et al of 8385 patients undergoing arthroplasty, gastrointestinal surgery, cardiovascular surgery, and hysterectomy found those listed with a penicillin allergy to have a 50% increased SSI risk which was largely due to patients receiving second-line agents for SAP. In addition, the labelling of penicillin allergy can lead to increased length of hospital stay, admission into intensive care units, increased hospital readmission rates and the promotion of antibiotic resistance.

A US study with over 50,000 patients demonstrated that patients labelled as penicillin allergic received significantly more prophylaxis or treatment with fluoroquinolones, clindamycin and vancomycin compared with control subjects.
Pharmacokinetice Alteration—Obesity

Patient risk factors for altered pharmacokinetics are frequently seen in surgical patients and can lead to variable requirements for SAP dosing. Obesity is increasing worldwide and the number of hospitalised patients with obesity is expected to grow in coming years. A cross-sectional study in the UK revealed approximately one in five inpatients were obese and those receiving antibiotics typically required more complicated dosing than non-obese patients. Obesity influences the pharmacokinetic disposition of common antibiotics used in SAP by alterations in volume of distribution, hepatic metabolism, renal clearance and protein binding, resulting in less predictable antibiotic exposure. In attempts to ensure adequate SAP dosage that provides sufficient tissue concentrations, minimise toxicity and prevent the development of antibiotic resistance, clinicians may need to tailor dosing to ideal body weight, lean body weight, or adjusted body weight recommendations. Examples of antibiotics which may require dose alteration in obesity include cefazolin, ceftriaxone, clindamycin, gentamicin, aztreonam, daptomycin and vancomycin. However, it is important to note that extended antibiotic exposure beyond 24 hours is one of the most common divergences from SAP guidelines, with approximately 30% of all SAP employed exceeding 24 hours. Intraoperative antibiotic re-dosing is sometimes employed in surgeries exceeding 4 hours. This is done to ensure serum and tissue concentrations exceed the microbial minimum inhibitory concentration (MIC) throughout the duration of surgery. Common examples include procedure durations exceeding two half-lives of the SAP utilised or in procedures where there is excessive blood loss, exceeding 1500mL. Key considerations for the clinician include factors that may affect antibiotic exposure time, such as extensive burns, concomitant medicines with drug–drug interactions or renal impairment.

Cefazolin pharmacokinetics suggest that additional doses could be administered in surgical procedures exceeding 3 hours in patients with normal renal function. SSI rates with such procedures are reportedly reduced (6.1% to 1.3%; P = <0.01) by re-dosing cefazolin or substituting another...
cephalosporin with a longer half-life, such as cefotetan. Similarly, intraoperative re-dosing of cefazolin has been adopted in prolonged cardiac surgery, where a 16% reduction in SSI has been demonstrated. An important study conducted in Brazil between 2011 and 2012 revealed the average length of surgery and total time spent in the operating theatre for 8337 procedures across various surgical subspecialties. Considerations and planning for possible antibiotic redosing could be achieved by reviewing usual surgery duration for longer procedures.

While not routinely re-dosed perioperatively, gentamicin dosing more than 30 minutes prior to surgical incision is generally recommended to allow for peak concentration-dependant activity. Gentamicin concentration upon surgery completion remains a predictable risk factor for SSI, where concentrations <0.5 mg/L were associated with up to an 80% infection rate in a very small study of 10 patients. Difficulties in SAP with gentamicin are highlighted during intraoperative blood loss and fluid replacement, where 2mg/kg doses of gentamicin for colorectal surgery did not achieve concentrations above the MIC of the organism in serum and/or tissue samples.

Optimising Current Practice Across Institutional Processes

The increasing frequency of community transmission and patient colonisation with ESBL producers, CRE, VRE as well as MRSA threatens the efficacy of routine SAP and perioperative patient pathways. This calls for a major overhaul of established perioperative processes, SAP guidelines and considerations of individual patient factors. Screening patients for colonisation with MROs will have an increasing role. Antimicrobial stewardship (AMS) programs, infection prevention and control initiatives, and quality use of medicines principles (right antibiotic(s), right dose and timing of administration) will have increasing importance (Figure 2). AMS programs are also effective in improving SAP in low- and middle-income countries (LMICs). The CDC-US provides guidance on the prevention of SSI, stipulating that SAP should only be used when appropriate and should follow established guidelines. Despite these influential recommendations, obstacles and challenges remain at the institutional level.

**Figure 2** Proposed flow chart for surgical antibiotic prophylaxis in the era of antibiotic resistance.

**Notes:** A proposed algorithm for screening patients with antibiotic resistance and considerations for surgical antibiotic prophylaxis. *Consult medical microbiology/ infectious diseases for appropriate management options for carbapenem-resistant Enterobacteriales (CRE), **Fosfomycin may be appropriate for transrectal prostate biopsy.

**Abbreviations:** AR, antibiotic resistance; ESBL producers, extended-spectrum β-lactamase-producing bacteria; FR-GNB, fluoroquinolone-resistant Gram-negative bacteria; VRE, vancomycin-resistant Enterococcus; MRSA, methicillin-resistant Staphylococcus aureus; SAP, surgical antibiotic prophylaxis.
Antimicrobial stewardship programs, clinical practice guidelines and protocols

A international survey of surgeons yielded 588 responses, with all considering antibiotic resistance to be an important concern and that local guidelines were of greater use than national guidelines.\textsuperscript{110} Key considerations for local guideline development are theatre workflow, organisms of concern, antibiotic selection, timing of dosage in relation commencement of surgery (knife-to-skin time), route of administration, duration of surgery and unforeseen delays in surgery time.\textsuperscript{19,111} Despite these considerations, many studies have demonstrated that even when such protocols and guidelines exist, they are often poorly adhered to.\textsuperscript{112–120} Studies investigating the implementation of AMS programs in the surgical setting have shown improved guideline adherence in several studies.\textsuperscript{121–123} Segala et al found that prior to the implementation of stewardship programs, antimicrobial prophylaxis was either not required, or appropriate but not given, occurred 41% of the time and that 29% of the cases were prescribed for longer than indicated. Post-implementation data from this study showed improvement in overall antibiotic appropriateness, duration and guideline adherence (36.6\% vs 57.9\%; \( p = <0.001 \)).\textsuperscript{124}

Cohen et al performed a large study across a cohort of 22,138 patients investigating the use of appropriate prophylactic antibiotics in various low-risk procedures and concluded there was no risk of increased antibiotic resistance in their cohort.\textsuperscript{125} Such data are promising for the use of protocols and their role in preventing the emergence of resistance within the surgical setting. The successful implementation of stewardship principles and protocols is demonstrated in previous studies involving a multidisciplinary team approach consisting of medical, pharmacy and nursing staff.\textsuperscript{121,123,126} Despite successful implementation of these programs, clinicians prescribing SAP are often unaware of existing protocols and therefore adherence is adversely impacted. Strategies to overcome these issues are likely to be improved by multidisciplinary engagement in the development and implementation of protocols.\textsuperscript{127}

The WHO recommend using a 19-step Surgical Safety Checklist (SSC) to capture critical tasks across three phases of the patients’ surgical journey: before induction of anaesthesia, before skin incision and prior to the patient leaving the operating room.\textsuperscript{128} A study across 8 countries following implementation of the SSC assessed complications and mortality occurring 30 days after non-cardiac surgery. SSC implementation decreased surgical complications (11\% to 7\%; \( p = <0.001 \)), and mortality (1.5\% to 0.8\%; \( p = 0.003 \)).\textsuperscript{129} The current WHO SSC (2009) aims to achieve SAP within 60 minutes prior to incision and assessment of patient allergies, both of which optimise appropriate antibiotic use.\textsuperscript{128} A retrospective cohort study of 772 patients undergoing various surgeries in the Netherlands investigated the impact of SSC implementation and optimisation on the timing of SAP (previously 0–60 minutes) prior to incision.\textsuperscript{130} Significantly fewer patients received SAP post-incision (decreasing from 12\% to 7.1\%) while SAP use within the pre-specified SAP time-frame (30–60 minutes) prior to incision improved.\textsuperscript{130} The issue of how well the WHO SSC is implemented into practice is a major consideration in both high- and low- to middle-income countries. While the evidence for SSC is strong, the evidence to supporting implementation has been lacking, particularly in LMICs. A recent systematic review found that the SSC is used with high fidelity in LMICs and strategies covering domains of training, adapting to context, provision of interactive assistance, stakeholder engagement and clinician support may offer solutions to augment implementation.\textsuperscript{131} Encouragingly, several studies in LMICs have shown that use of the WHO SSC is possible and can be sustained.\textsuperscript{132–134} Furthermore, when scale-up of the WHO SSC underwent economic evaluation in three African countries (Benin, Cameroon and Madagascar) it was found to be very cost-effective with every USD$1 spent producing a potential return on investment of USD$9–62.\textsuperscript{135}

Prescreening Patients and Decolonisation

In attempts to curb institutional transmission of antibiotic resistance within the perioperative setting, focus has shifted towards prescreening patients prior to surgery and/or hospital admission. This strategy was seen after the emergence of MRSA, whereby prescreening for MRSA by the use of nasal swabs and subsequently patient isolation, decolonisation and tailored SAP has been adopted in some institutions.\textsuperscript{136} A multi-site study conducted across a number of European countries showed that combinations of prescreening, patient isolation and decolonisation 5-days prior to clean surgery (using chlorhexidine body wash and nasal mupirocin) decreased MRSA infection by 17\%.\textsuperscript{137} Further, in a study of patients undergoing cardiac surgery, targeted prophylaxis with vancomycin (± standard of care, cefazolin) in patients colonised with MRSA reduced SSI (OR 0.58; 95\% CI 0.40–0.86).\textsuperscript{138}

There are challenges with ß-lactamase-producing Enterobacterales, where bacterial carriage in the gastrointestinal tract limits the ability of decolonisation and is recognised in the WHO Surgical Site Infection
Prevention Guidelines. Dubinsky-Pertzov et al screened surgical patients given routine SAP for ESBL colonisation prior to gastrointestinal surgery, and found SSI rates in those colonised more than double that of non-ESBL carriers (OR 2.36; 95% CI 1.50–3.71).

The increasing prevalence of fluoroquinolone resistance and the longstanding use for prophylaxis in transrectal prostate biopsy has received critique by the European Association of Urology, suggesting prescreening of these patients for fluoroquinolone resistance or the use of prophylactic Fosfomycin. Recommendations for fosfomycin in transrectal prostate biopsy are supported by a meta-analysis, which shows improved patient outcomes compared with ciprofloxacin standard of care, although data in this meta-analysis came from some countries with high rates of ciprofloxacin resistance. Additionally, increasing fluoroquinolone resistance has been seen in patients with \textit{P. aeruginosa} SSI post endoscopic sinus surgery.

**Timing of Surgical Antibiotic Prophylaxis**

The premise of appropriate timing of SAP stems from the pharmacokinetic and pharmacodynamic properties of the antibiotic. The most commonly employed SAP agents are cephalosporins (ie cefazolin) which are traditionally administered up to 60 minutes prior to surgical incision (knife-to-skin time). This allows appropriate time for peak concentration, distribution and penetration into the peripheral tissue and time above the MIC of the anticipated organism. Evidence for administration of cefazolin <120 minutes prior to incision originated from a study in 1992 consisting of 2847 patients. A subsequent meta-analysis of over 54,552 patients (from 14 studies) concurred with this finding. The timing of vancomycin and fluoroquinolone administration for SAP differs to cephalosporin due to the increased infusion time required with these agents. Typically, commencement of vancomycin and fluoroquinolone infusions commences 1-hour prior to surgical incision, as shortened infusions can cause adverse effects, including “red-man syndrome” with vancomycin and venous irritation with fluoroquinolones. While standard infusion times may vary at an institutional level, vancomycin is typically administered at a rate of 1g/hour. Similarly, ciprofloxacin is infused over 60 minutes and levofloxacin over 60 or 90 minutes for doses of ≤500mg and >500mg, respectively.

Timing of antibiotic administration remains a challenging component of SAP and clinical practice can be divergent with key guidelines. Studies have shown improved timing of antibiotic administration following antibiotic stewardship initiatives in high-income countries, though mixed results have been observed from similar studies in LMICs. A study performed in Egypt found that after AMS initiatives, appropriate timing of SAP first dose improved from 6.7% to 38.7% (p = <0.01). A study conducted in Ethiopia found that the recorded timing of SAP administration remained poor post-implementation of an institutional SAP protocol 69.3% to 63.9% (p = 0.26).

While various studies have investigated the impact of SAP timing, there are many nuances within the surgical environment that can hinder appropriate timing of antibiotic administration. Tan et al interviewed surgeons, anaesthetists and perioperative administrators across two large hospitals in the US and highlighted key obstacles affecting SAP: 1) timing as lower priority to the clinician, 2) inconvenience in patient management, 3) potential to disrupt workflow, 4) limited communication between the treating team and differences in role perception and clinician hierarchy.

**Team Communications, and Cultures of Practice**

Research has highlighted the power dynamics that exist in surgical teams in relation to antibiotic decision-making, including an individualistic and hierarchical culture, which may limit integrated care in surgical pathways. Historically, AMS initiatives have overlooked surgical specialties, with the notion that surgical teams are more difficult to engage with. Where they do exist, the focus has been on SSI prevention and SAP. Antibiotic prescribing in hospital settings is ubiquitous and doctors of different specialties must be able to diagnose and treat infections. The issue of ownership of the antibiotic prescription or order is often not clear, particularly in surgical pathways where multiple healthcare professionals have a role to play. The issue of ownership is also unclear when it comes to SAP, with surgeons and anaesthetists both identified as bearing the responsibility for the selection and administration of initial and any follow-up doses. The issue of clinician autonomy taking precedence over policy and guidelines is an important factor, which can influence the selection of antibiotics and the duration of SAP. Studies have demonstrated that SAP is often prolonged beyond a single dose and is
used as a safety net to allay the surgeons fears of SSI and post-operative complications. A systematic review of the effect of post-operative continuation of SAP has demonstrated no benefits over single-dose therapy. Therefore, we need to communicate the risks associated with prolonged antibiotic use more effectively with surgical teams, to facilitate their decision-making and their ability to understand infection-related risks associated with their surgical intervention versus the risks associated with prolonged use of antibiotics. Team communication both peri- and post-operatively also impacts the infection-related care that patients receive, including SAP, and SSI-related care. Research is needed to identify effective mechanisms for interdisciplinary work across the surgical pathway including within the theatre between surgeons and anaesthetists. The roles of anaesthetists in SAP need to be more clearly defined to enable a more sustainable path to optimising SAP.

**Alternative Agents and Means to Approach Antibiotic Resistance**

Machine learning, while still in early stages, is an evolving field for the prediction and management of patients colonised with MRsOs. The use of machine learning aims to predict the presence of resistance by using genomic data, assisting the clinician with early diagnosis, prevention and provide guidance on treatment options. Early-stage trials within ICU departments in Greece have used machine learning to review patients with antibiotic-resistant bacteria and recommend appropriate empirical antimicrobials. Other promising options of machine learning are the ability to utilise health registry data to identify resistance patterns and promote stewardship programs within the hospital environment. While not currently trialled for SAP, such systems may be appropriate to assist clinicians in the growing climate of antibiotic resistance.

The slow rate of new antimicrobial development and at times diminishing efficacy of existing antibiotics has led to the investigation of alternative options, such as bacteriophage therapy and faecal microbiota transplant (FMT). While still in their discovery phase in medicine, bacteriophages are viruses with restricted bacterial activity often resulting in bacterial cell lysis. To date, application and evidence of bacteriophage therapy is limited to small case studies and experimental trials. A series of patients (n=8) in Finland with multidrug-resistant bacterial infection post-cardiothoracic surgery received conventional targeted antibiotics and bacteriophages, resulting in successfully treated infections in 7/8 (87%) patients. Hypothesised applications of bacteriophages in the surgical setting with topical application of phage solutions to a surgical wound before closure are proposed by Brives and Pourraz. The growing concerns of mupirocin resistant MRSA and difficulty in eradicating mucosal *Staphylococcus* carriage has sparked interest in the use of bacteriophage for nasal decolonisation of MRSA; studies are currently limited to animal models but show favourable efficacy. The role of FMT is an emerging treatment for multidrug-resistant organisms of the gastrointestinal tract, with use increasingly common for the treatment of refractory *C. difficile* infection. Treatment outcomes in these patients are showing response rates in approximately 90% of the cases. Currently, there is limited evidence supporting gastrointestinal MRO decolonisation with antibiotic therapy, where use may potentiate resistance due to gastrointestinal rebound of resistant bacteria. FMT is a novel method, with growing interest in its role in gastrointestinal decolonisation of multidrug-resistant bacteria. A recent systematic review showed approximately 50% of the patients to have successful gastrointestinal decolonisation when treated with FMT for multidrug-resistant bacteria. Higher rates of decolonisation were noted for *P. aeruginosa* than *K. pneumoniae* (ESBL or NDM-1); however, it is important to note the studies were of low-quality evidence (high risk of bias), small sample size (total 52 patients) and decolonisation was temporary.

**Conclusion**

Overcoming challenges in SAP in the modern era of antibiotic resistance is essential to optimise patient care and surgical outcomes. The increasing and complex issue of antibiotic-resistant bacteria and strategies required to facilitate appropriate SAP are becoming increasingly challenging for those working in the surgical setting. Optimising current practice and implementing appropriate antibiotic stewardship initiatives through collaborative multidisciplinary teams is likely to remain fundamental to mitigate AR and limit SSI with resistant organisms. Future research is urgently required to establish effective and appropriate alternative antibiotics for surgical antibiotic prophylaxis in those colonised with antibiotic-resistant bacteria. Currently, a targeted approach to using alternative antibiotics based on pre-colonisation data, antibiotic
sensitives and/or spectrum of antibiotic activity could be considered.

Key Considerations
- The incidence of antibiotic-resistant bacteria is increasing across the world: threatening the efficacy of surgical antibiotic prophylaxis and increasing the risk of surgical site infection.
- Drivers of antibiotic resistance are multifactorial and consist of misuse/inappropriate use across many areas, including primary and tertiary care.
- Awareness of common and problematic resistant bacteria and appropriate prophylaxis is imperative to optimise surgical outcomes, these include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriales (CRE), fluoroquinolone-resistant Gram-negative bacteria, and extended-spectrum β-lactamase (ESBL)-producing bacteria.
- There is a lack of well-established data to support the use of broader spectrum or targeted alternative agents in those colonised with antibiotic-resistant bacteria, future research is essential on this topic.
- In the absence of high-quality data, a targeted approach using antibiotics in those colonised with antibiotic-resistant bacteria and those with a high risk of SSI may be an option. Inappropriate use of broad-spectrum antibiotics in the absence of drug-resistant bacteria and low risk of SSI is likely to potentiate antibiotic resistance, provide no benefit in patient care and may be potentially harmful.
- In addition to the consideration of targeted prophylaxis, optimisation of current practice is essential to slow the emergence of antibiotic resistance. Such steps occur at the patient and institutional levels. Steps of optimisation at a patient level include rationalisation of appropriate antibiotic use in those with a documented penicillin allergy and tailored dosing in those with concurrent obesity. Steps of optimisation at the institutional level include developing and implementation of antibiotic stewardship programs, which involve staff in the perioperative setting and ensuring appropriate timing of administration.

Acknowledgments
EC, AL and RM acknowledge funding from the Economic and Social Research Council (ESRC) and the National Institute for Health Research ASPIRES project (Antibiotic use across Surgical Pathways: Investigating, Redesigning and Evaluating Systems) (https://www.imperial.ac.uk/arc/aspires/). ASPIRES aims to address antimicrobial resistance and improve clinical outcomes optimising antibiotic usage along surgical pathways. EC acknowledges the National Institute for Health Research, UK Department of Health [HPRU-2012-10047] in partnership with Public Health England. The funders had no role in the design and conduct of this review; collection, management, analysis, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclosure
Dr Esmita Charani reports personal fees from Pfizer, outside the submitted work. Dr Andrew JM Leather reports grants from Economic and Social Research Council (ESRC). The authors report no other conflicts of interest in this work.

References
17. World Health Organization. Protocol for surgical site infection surveillance with a focus on settings with limited resources; 2018.


